AKESO INC. O.N. (F:4RY) — Market Cap & Net Worth
Market Cap & Net Worth: AKESO INC. O.N. (4RY)
AKESO INC. O.N. (F:4RY) has a market capitalization of $11.71 Billion (€10.02 Billion) as of June 6, 2026. Listed on the F stock exchange, this Germany-based company holds position #1998 globally and #419 in its home market, demonstrating a -12.30% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AKESO INC. O.N.'s stock price €10.88 by its total outstanding shares 921143176 (921.14 Million). Review AKESO INC. O.N. (4RY) total liabilities to assess the company's total debt and financial obligations.
AKESO INC. O.N. Market Cap History: 2020 to 2026
AKESO INC. O.N.'s market capitalization history from 2020 to 2026. Data shows growth from $4.09 Billion to $11.71 Billion (23.62% CAGR).
AKESO INC. O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AKESO INC. O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.23x
AKESO INC. O.N.'s market cap is 4.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $3.75 Billion | $225.63 Million | -$1.07 Billion | 16.61x | N/A |
| 2022 | $5.34 Billion | $837.66 Million | -$1.17 Billion | 6.38x | N/A |
| 2023 | $5.76 Billion | $4.53 Billion | $2.03 Billion | 1.27x | 2.84x |
| 2024 | $7.70 Billion | $2.12 Billion | -$514.51 Million | 3.63x | N/A |
| 2025 | $12.92 Billion | $3.06 Billion | -$1.11 Billion | 4.23x | N/A |
Competitor Companies of 4RY by Market Capitalization
Companies near AKESO INC. O.N. in the global market cap rankings as of June 6, 2026.
Key companies related to AKESO INC. O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #225 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #425 globally with a market cap of $64.77 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #583 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #600 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #225 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $441.74 |
| #425 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.77 Billion | $628.73 |
| #583 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #600 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
AKESO INC. O.N. Historical Marketcap From 2020 to 2026
Between 2020 and today, AKESO INC. O.N.'s market cap moved from $4.09 Billion to $ 11.71 Billion, with a yearly change of 23.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €11.71 Billion | -9.38% |
| 2025 | €12.92 Billion | +67.83% |
| 2024 | €7.70 Billion | +33.64% |
| 2023 | €5.76 Billion | +7.86% |
| 2022 | €5.34 Billion | +42.53% |
| 2021 | €3.75 Billion | -8.42% |
| 2020 | €4.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 5th, 2026 the market cap of AKESO INC. O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.71 Billion USD |
| MoneyControl | $11.71 Billion USD |
| MarketWatch | $11.71 Billion USD |
| marketcap.company | $11.71 Billion USD |
| Reuters | $11.71 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About AKESO INC. O.N.
Akeso, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer, lung cancer, and liver cancer; and AK112, a PD-1/VEGF bi-specific antibody to treat lung cancer, biliary tract cancer, head and neck squamous cell car… Read more